Filing Details

Accession Number:
0001209191-21-053642
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-08-27 16:55:43
Reporting Period:
2021-08-27
Accepted Time:
2021-08-27 16:55:43
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1815442 Kymera Therapeutics Inc. KYMR Biological Products, (No Disgnostic Substances) (2836) 812992166
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1821188 Richard Chesworth C/O Kymera Therapeutics, Inc.
200 Arsenal Yards Blvd., Suite 230
Watertown MA 02472
Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-08-27 33,779 $20.00 33,779 No 4 M Direct
Common Stock Disposition 2021-08-27 33,779 $60.12 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2021-08-27 33,779 $0.00 33,779 $20.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
263,340 2030-08-19 No 4 M Direct
Footnotes
  1. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.
  2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $59.99 to $60.69. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
  3. Twenty-five percent (25%) of the shares subject to this option vested and became exercisable on August 17, 2021, and the remainder of the shares shall vest in equal monthly installments for a period of thirty-six (36) months thereafter.